TAE Technologies, Inc.
https://tae.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From TAE Technologies, Inc.
Finance Watch: New Funding Available For Antibacterials, Start-Ups
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
New Easton Capital Fund Structure Fits The Times
Easton capital has secured roughly $20 million for a “special situations” fund of unusual design. The new fund is a five-year commitment between general partners and limited partners with the potential for three one-year extensions. Limited partners estimate the average life of a typical venture fund to be roughly 15 years. Easton Capital’s fund will be concluded in half the time.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover Edwards Lifescience's Sapien TAVI device, and news from emerging neurostimulation companies.
Recent Financings of Private Companies (09/11)
Start-Up's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation and reagent sectors.
Company Information
- Industry
- Diversified
- Other Names / Subsidiaries
-
- TAE Life Sciences
- Tri Alpha Energy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice